FDA cites Chinese firm's manufacturing processes for hepari
<p><a href="http://us.rd.yahoo.com/dailynews/rss/health/*http://news.yahoo.com/s/ap/20080421/ap_on_he_me/heparin"><img src="http://d.yimg.com/us.yimg.com/p/ap/20080421/capt.f928e300ed2f4ee7ac7fc294c32eb1f1.heparin_china_dcsa107.jpg?x=130&y=92&q=85&sig=QcBB9jSZsomoxzIjNtP53A--" align="left" height="92" width="130" alt="Chinese Embassy spokesman Wang Baodong, right, introduces Professor Jin Shaohong, deputy director-general of China's National Institute for the Control of Pharmaceutical and Bilogical Products, during a news conference at the Chinese Embassy in Washington, Monday, April 21, 2008, to defend against allegations that a Chinese factory component of the blood-thinning drug Heparin was to blame for problems with American patients. (AP Photo/J. Scott Applewhite)" border="0" /></a>AP - China and the United States traded charges Monday about whether a contaminant in the blood thinner heparin caused severe allergic reactions linked to as many as 81 deaths.</p><br clear="all"/>

Read more...